Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2024-01-17 00:00:00 ET · period of report 2024-01-16 · accession 0001415889-24-001313 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-17 | 2024-01-16 | QNCX | Thye Dirk | CEO, Dir | M - OptEx | $0.7932 | +240.5K | 539.4K | +80% | +$190.8K |
| DM | 2024-01-17 | 2024-01-16 | QNCX | Thye Dirk | CEO, Dir | M - OptEx | $0.00 | -240.5K | 450.0K | -35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-16 | M | A | 149,999 | $0.94 | 689,441 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-16 | M | A | 90,531 | $0.55 | 539,442 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2024-01-16 | M | D | 90,531 | $0.00 | 115,860 | D | $0.55 · — to 2022-03-27 | 90,531 Common Stock | (F1) The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2024-01-16 | M | D | 149,999 | $0.00 | 450,001 | D | $0.94 · — to 2033-01-31 | 149,999 Common Stock | (F2) The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. |